All content for Frankly Speaking About Family Medicine is the property of Pri-Med and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A weekly Podcast series covering newsworthy topics in primary care medicine. Thoughts? Suggestions? Email us at
FranklySpeaking@pri-med.com
A Side-by-Side Look at GLP-1 RAs for Weight Loss - Frankly Speaking Ep 451
Frankly Speaking About Family Medicine
12 minutes
2 weeks ago
A Side-by-Side Look at GLP-1 RAs for Weight Loss - Frankly Speaking Ep 451
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-451
Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year.
Episode resource links:
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.
Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199-217.
Wen J, Syed B, Nadora D, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol Diabetes Metab. 2025;8(3):e70045.
Guest: Alan M. Ehrlich, MD, FAAFPMusic Credit: Matthew Bugos
Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com
Frankly Speaking About Family Medicine
A weekly Podcast series covering newsworthy topics in primary care medicine. Thoughts? Suggestions? Email us at
FranklySpeaking@pri-med.com
